ArticleEpilepsia2026
Cardiovascular events and mortality in adults with late onset seizures: Focus on enzyme-modulating antiseizure medications.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUsing a Dutch insurance claims registry, we examine whether people with epilepsy have an increased risk of major ischemic cardiovascular events or death compared to people without epilepsy. We also assess whether this risk differs between users of enzyme-modulating and non-enzyme-modulating antiseizure medications (ASMs).
methodsThis nationwide study included adults ≥50 years old in the VEKTIS registry. Incident seizure cases were matched 2:1 to controls by age, sex, and region. ASM prescriptions (≥6 months) were classified as enzyme-modulating or non-enzyme-modulating. The primary outcome was a composite event over 5-year follow-up. Cox models adjusted for age, sex, and baseline cardiovascular medications.
resultsWe matched 8728 cases to 17 445 controls (56% male, median age = 67 years, range = 50-102). During follow-up, 6895 events occurred. Seizure disorder was associated with a higher cardiovascular risk than controls (hazard ratio [HR] = 2.30, 95% confidence interval [CI] = 2.19-2.41, p < .001), particularly early after diagnosis. Older age and cardiovascular medication use increased risk, whereas female sex was protective. Among 1758 participants with seizures treated with ASM, 656 events occurred. The enzyme-modulating ASM group showed a nonsignificant trend toward higher risk than the non-enzyme-modulating ASM group (HR = 1.14, 95% CI = .97-1.34, p = .12). Time-varying models suggested a lower risk with current enzyme-modulating ASM exposure compared with non-enzyme-modulating ASMs (HR = .80, 95% CI = .70-.92, p = .001). There was an increased risk with cumulative exposure (HR = 1.41 per year of past enzyme-modulating ASM exposure, 95% CI = 1.30-1.54, p < .001). SIGNIFICANCE: People with seizures face higher cardiovascular risk, especially shortly after diagnosis. Although short-term analyses showed no clear differences between ASM categories, longer term and cumulative exposure to enzyme-modulating ASMs was associated with modestly increased risk. Findings are generalizable to routine care, although further work is needed to clarify time- and drug-specific cardiovascular effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.